{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:43:14Z","timestamp":1790026994128,"version":"4.0.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82070124"],"award-info":[{"award-number":["No.82070124"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["No.2020CFA065"],"award-info":[{"award-number":["No.2020CFA065"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundamental Research Support Program of Huazhong University of Science and Technology","award":["No.5003530166"],"award-info":[{"award-number":["No.5003530166"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R\/R) B-cell neoplasms. Compared with autologous CAR-T cell therapy, off-the-shelf universal CAR-T cell therapies have many potential benefits, such as immediate accessibility for patients, stable quality due to industrialized manufacturing and additional infusions of CAR-T cells with different targets. However, critical challenges, including graft-versus-host disease and CAR-T cell elimination by the host immune system, still require extensive research. The most common technological approaches involve modifying healthy donor T cells via gene editing technology and altering different types of T cells. This article summarizes some of the latest data from preclinical and clinical studies of off-the-shelf CAR-T cell therapies in the treatment of R\/R B-cell malignancies from the 2023 ASH Annual Meeting (ASH 2023).<\/jats:p>","DOI":"10.1186\/s13045-024-01550-9","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T13:01:54Z","timestamp":1715000514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting"],"prefix":"10.1186","volume":"17","author":[{"given":"Yun","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"issue":"Suppl 1","key":"1550_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood-2023-189196","volume":"142","author":"FL Locke","year":"2023","unstructured":"Locke FL, Munoz JL, Tees MT, et al. ALLO-647 for lymphodepletion in the allogeneic CAR T setting: safety experience with ALLO-501\/501A in patients (Pts) with relapsed\/refractory (r\/r) large B-cell and follicular lymphomas. Blood. 2023;142(Suppl 1):2095\u20132095.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR2","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1182\/blood-2023-187252","volume":"142","author":"N Jain","year":"2023","unstructured":"Jain N, Chevallier P, Liu H, et al. Updated results of the phase I BALLI-01 trial of UCART22 process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by cellectis biologics, in patients with relapsed or refractory (R\/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2023;142(Suppl 1):4847\u20134847.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR3","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1182\/blood-2023-186570","volume":"142","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Ramakrishnan A, Pierola AA, et al. Preliminary results of Nathali-01: a first-in-human phase I\/IIa study of UCART20x22, a dual allogeneic CAR-T cell product targeting CD20 and CD22, in relapsed or refractory (R\/R) non-hodgkin lymphoma (NHL). Blood. 2023;142(Suppl 1):2110\u20132110.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR4","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood-2023-182430","volume":"142","author":"B Dholaria","year":"2023","unstructured":"Dholaria B, Kocoglu MH, Kin A, et al. Early safety results of P-BCMA-ALLO1, a fully allogeneic chimeric antigen receptor T-Cell (CAR-T), in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2023;142(Suppl 1):3479\u20133479.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR5","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/blood-2023-180873","volume":"142","author":"J Spehr","year":"2023","unstructured":"Spehr J, Meyer JE, Loff S, et al. Functional characterization and optimization of switchable allogeneic chimeric antigen receptor T cells for targeting CD19 and CD20 in B cell malignancies. Blood. 2023;142(Suppl 1):2059\u20132059.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR6","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1182\/blood-2023-187096","volume":"142","author":"A Johnson","year":"2023","unstructured":"Johnson A, Wright H, Hu X, et al. Hypoimmune, allogeneic CD22-directed CAR T cells that evade innate and adaptive immune rejection for the treatment of large B cell lymphoma patients that are relapsed\/refractory to CD19-directed CAR T cell therapy. Blood. 2023;142(Suppl 1):3437\u20133437.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR7","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2023-189052","volume":"142","author":"Y Hu","year":"2023","unstructured":"Hu Y, Wei G, Fu S, et al. Intracellular retention of Tcr\u03b1\u03b2\/CD3 to generate novel allogeneic CAR-T cells (ThisCART19A) with enhanced antitumor potency for treating B-ALL. Blood. 2023;142(Suppl 1):2111\u20132111.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR8","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1182\/blood-2023-180753","volume":"142","author":"S Shahid","year":"2023","unstructured":"Shahid S, Flynn GC, Mauguen A, et al. Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies. Blood. 2023;142(Suppl 1):3476\u20133476.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR9","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1182\/blood-2023-181199","volume":"142","author":"S Cha","year":"2023","unstructured":"Cha S, Charbonneau M, Brito A, Habibi A, Pham C, Nguyen C. ATA3431: allogeneic CD19\/CD20 bispecific CAR EBV T cells for the treatment of B-cell malignancies. Blood. 2023;142(Suppl 1):4800\u20134800.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR10","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood-2023-181919","volume":"142","author":"MA Moreno","year":"2023","unstructured":"Moreno MA, Kennedy-Wilde J, Wrong AD, et al. Expansion, persistence and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR gamma delta T cell therapy, in patients with relapsed\/refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Blood. 2023;142(Suppl 1):3478\u20133478.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR11","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/blood-2023-187658","volume":"142","author":"L Leong","year":"2023","unstructured":"Leong L, Narula M, Heslop HE, Brenner MK, Mamonkin M, Watanabe N. Combining apoptotic resistance and cytokine signaling to improve persistence and anti-tumor activity of CAR V\u03b42 T cells in vivo. Blood. 2023;142(Suppl 1):3440\u20133440.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR12","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/blood-2023-173356","volume":"142","author":"Y Hattori","year":"2023","unstructured":"Hattori Y, Kubo T, Nagano S, et al. Anti-CD38-CAR IPS-derived cytotoxic T lymphocytes efficiently eliminate myeloma cells treated with daratumumab and isatuximab in vitro and in vivo. Blood. 2023;142(Suppl 1):3312\u20133312.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1550_CR13","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood-2023-189149","volume":"142","author":"X Xiao","year":"2023","unstructured":"Xiao X, Lei W, Jiang H, et al. A phase 1 study of RJMty19: anti-CD19 humanized CAR-engineered allogeneic double negative T cells in adults with B-cell non-Hodgkin\u2019s lymphoma. Blood. 2023;142(Suppl 1):2094\u20132094.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01550-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01550-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01550-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T13:07:04Z","timestamp":1715000824000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01550-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1550"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01550-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}